North America Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Publish Reports
  • Apr 2019
  • North America
  • 350 Pages
  • No of Tables: 22
  • No of Figures: 52

North America Scleroderma Therapeutics Market By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2026 – Industry Trends and Forecast to 2026

Scleroderma is an auto-immune disease of unknown etiology and is characterized by fibrosis and microvascular injury in affected organs. In this disease, Raynaud’s phenomenon is an initial symptom and shows puffiness of fingers. There are two types of scleroderma - localized scleroderma and limited cutaneous systemic sclerosis. Localized sclerosis shows plaques of fibrotic skin and subcutaneous tissue which further occurs as linear fibrotic bands on extremities such as skin and deeper tissue. Hence, it has two types in localized scleroderma and they are morphea and linear scleroderma. As per the studies carried out by researchers, it has been found that the disease occurs due to the changes in certain parameter in environment or changes in certain gene in human. The symptoms involves in this disease is abnormalities on the skin, painful joints, morning stiffness, fatigue, and/or weight loss and many others.

There is no drug or treatment available to treat scleroderma but there are certain drugs available which can be used in treating the disease associated to scleroderma such as kidney disease, Heartburn (acid reflux), Raynaud's phenomenon and others. Some of them are aspirin, naproxen, ibuprofen and many others.

North America scleroderma therapeutics market is expected to register a healthy CAGR in the forecast period of 2019 to 2026.

Segmentation: North America Scleroderma Therapeutics Market

North America scleroderma therapeutics market is segmented into four notable segments such as type, treatment type, end user.

  • On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma

    • In March 2019, Sanofi received FDA (Food and Drug Administration) approved Dupixent (dupilumab) which is useful for moderate-to-severe atopic dermatitis in adolescents. It is used for treating the skin related issues as it clears the skin and reduced itching in adolescents. With this approval the company has increased its portfolio and also increased its business bry provides product everywhere around the world.

  • On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy.

    • In February 2018, Novartis's Sandoz division received U.S. approval for a larger dosage of its product called Glatopa drug which is useful for treatment of multiple sclerosis patients, approval of product reinforce company’s leadership in market.

  • On the basis of end user, the North America scleroderma therapeutics market is segmented into hospital, speciality clinics, homecare settings and others

    • In May 2017, F. Hoffmann-La Roche Ltd received the U.S. Food and Drug Administration (FDA) for its product Actemra/RoActemra (tocilizumab) subcutaneous injection that is useful for treatment of GCA. GCA chronic and severe autoimmune condition and Actemra/RoActemra (tocilizumab) is the first FDA approved treatment for GCA in adults. It is the 6th approval after its first U.S. launch in 2010.

Competitive Analysis: North America Scleroderma Therapeutics Market

Some of the prominent participants operating in this market are Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca, Daval International Limited and others.

Recent Development:

  • In February 2018, Novartis's Sandoz division received U.S. approval for a larger dosage of its product called Glatopa drug which is useful for treatment of multiple sclerosis patients, approval of product reinforces company’s leadership in market.
  • In September 2015, Pfizer Inc. acquired Hospira, Inc. who is a global leader in biosimilars. With this acquisition Pfizer Inc. increased their product portfolio, employees and presence. The company has strengthened their position by providing broadest and most diverse portfolios in market.
  • In August 2015, Pfizer and Synthon (Netherlands) entered into the U.S. commercialization agreement for potential generic treatment of multiple sclerosis. With this partnership the company has established its strong presence in the U.S. for glatiramer acetate which is a high quality product.

Research Methodology: North America Scleroderma Therapeutics Market

Primary Respondents:

Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.


SKU-

TABLE OF CONTENTS NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED 2.2 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7 DBMR MARKET POSITION GRID 2.8 TIME LINE 2.9 MULTIVARIATE MODELLING 2.10 SECONDARY SOURCES 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING CASES OF SCLERODERMA 3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S. 3.1.3 INCREASING MERGER AND ACQUISITIONS

3.2 RESTRAINTS

3.2.1 LACK OF CURATIVE TREATMENT 3.2.2 STRINGENT REGULATIONS 3.2.3 COUNTERFEIT PRODUCTS

3.3 OPPORTUNITY

3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS

3.4 CHALLENGE

3.4.1 SIDE EFFECTS OF DRUGS

4 EXECUTIVE SUMMARY 5 PREMIUM INSIGHTS 6 PIPELINE PRODUCTS 7 EPIDEMIOLOGY

7.1 HISTORY OF SCLERODERMA: 7.2 RECENT INCIDENCE AND PREVALENCE: 7.3 CAUSE OF SCLERODERMA: 7.4 SYMPTOMS OF SCLERODERMA: 7.5 MANAGING SCLERODERMA:

8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE

8.1 OVERVIEW 8.2 SYSTEMIC SCLERODERMA

8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME 8.2.2 DIFFUSE SYSTEMIC SCLEROSIS

8.3 LOCALIZED SCLERODERMA

8.3.1 MORPHEA 8.3.2 LINEAR SCLERODERMA

9 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE

9.1 OVERVIEW 9.2 DRUG TREATMENT

9.2.1 DRUG TREATMENT, BY TYPE

9.2.1.1 ANTI-INFLAMMATORY DRUGS 9.2.1.2 IMMUNOSUPPRESSANTS 9.2.1.3 CORTICOSTEROIDS 9.2.1.4 PROTON PUMP INHIBITORS 9.2.1.5 CALCIUM CHANNEL BLOCKERS 9.2.1.6 ACE INHIBITORS 9.2.1.7 H2 BLOCKERS 9.2.1.8 PDE5 INHIBITORS 9.2.1.9 PROSTACYCLIN ANALOGUES 9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS 9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM) 9.2.1.12 OTHERS

9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL

9.2.2.1 HOSPITAL PHARMACY 9.2.2.2 RETAIL PHARMACY 9.2.2.3 ONLINE PHARMACY 9.2.2.4 OTHERS

9.3 SURGICAL TREATMENT 9.4 THERAPY

9.4.1 ULTRAVIOLET LIGHT THERAPY 9.4.2 PHYSICAL THERAPY 9.4.3 OTHERS

10 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER

10.1 OVERVIEW 10.2 HOSPITAL 10.3 SPECIALTY CLINICS 10.4 HOMECARE SETTINGS 10.5 OTHERS

11 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY

11.1 NORTH AMERICA

11.1.1 U.S. 11.1.2 CANADA 11.1.3 MEXICO

12 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 COMPANY PROFILES

13.1 ASTRAZENECA

13.1.1 COMPANY SNAPSHOT 13.1.2 REVENUE ANALYSIS 13.1.3 GEOGRAPHICAL PRESENCE 13.1.4 PRODUCT PORTFOLIO (PIPELINE) 13.1.5 RECENT DEVELOPMENTS

13.2 F. HOFFMANN-LA ROCHE LTD

13.2.1 COMPANY SNAPSHOT 13.2.2 REVENEUE ANALYSIS 13.2.3 GEOGRAPHICAL PRESENCE 13.2.4 PRODUCT PORTFOLIO 13.2.5 RECENT DEVELOPMENTS

13.3 NOVARTIS AG

13.3.1 COMPANY SNAPSHOT 13.3.2 REVENEUE ANALYSIS 13.3.3 GEOGRAPHICAL PRESENCE 13.3.4 PRODUCT PORTFOLIO 13.3.5 RECENT DEVELOPMENTS

13.4 PFIZER INC.

13.4.1 COMPANY SNAPSHOT 13.4.2 REVENEUE ANALYSIS 13.4.3 GEOGRAPHICAL PRESENCE 13.4.4 PRODUCT PORTFOLIO 13.4.5 RECENT DEVELOPMENTS

13.5 ABBVIE INC.

13.5.1 COMPANY SNAPSHOT 13.5.2 REVENEUE ANALYSIS 13.5.3 GEOGRAPHICAL PRESENCE 13.5.4 PRODUCT PORTFOLIO 13.5.5 RECENT DEVELOPMENTS

13.6 ACTIVE BIOTECH AB.

13.6.1 COMPANY OVERVIEW 13.6.2 REVENUE ANALYSIS 13.6.3 PRODUCT PORTFOLIO 13.6.4 RECENT DEVELOPMENT

13.7 ALLERGAN

13.7.1 COMPANY SNAPSHOT 13.7.2 REVENEUE ANALYSIS 13.7.3 GEOGRAPHICAL PRESENCE 13.7.4 PRODUCT PORTFOLIO 13.7.5 RECENT DEVELOPMENTS

13.8 ARGENTIS PHARMACEUTICALS, LLC.

13.8.1 COMPANY OVERVIEW 13.8.2 PRODUCT PORTFOLIO 13.8.3 RECENT DEVELOPMENTS

13.9 BRISTOL-MYERS SQUIBB COMPANY

13.9.1 COMPANY OVERVIEW 13.9.2 REVENUE ANALYSIS 13.9.3 GEOGRAPHICAL PRESENCE 13.9.4 PRODUCTS PORTFOLIO 13.9.5 RECENT DEVELOPMENTS

13.10 DAVAL INTERNATIONAL LIMITED

13.10.1 COMPANY SNAPSHOT 13.10.2 GEOGRAPHICAL PRESENCE 13.10.3 PRODUCT PORTFOLIO 13.10.4 RECENT DEVELOPMENT

13.11 GLAXOSMITHKLINE PLC.

13.11.1 COMPANY OVERVIEW 13.11.2 REVENUE ANALYSIS 13.11.3 GEOGRAPHICAL PRESENCE 13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT) 13.11.5 RECENT DEVELOPMENT

13.12 JOHNSON & JOHNSON SERVICES, INC.

13.12.1 COMPANY OVERVIEW 13.12.2 REVENUE ANALYSIS 13.12.3 GEOGRAPHICAL PRESENCE 13.12.4 PRODUCT PORTFOLIO (PIPELINE) 13.12.5 RECENT DEVELOPMENTS

13.13 SANOFI

13.13.1 COMPANY SNAPSHOT 13.13.2 REVENEUE ANALYSIS 13.13.3 GEOGRAPHICAL PRESENCE 13.13.4 PRODUCT PORTFOLIO 13.13.5 RECENT DEVELOPMENT

13.14 VIDA THERAPEUTICS INC.

13.14.1 COMPANY OVERVIEW 13.14.2 PRODUCT PORTFOLIO 13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE 15 RELATED REPORTS

 

LIST OF TABLES NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

TABLE 1 INSIGHTS ABOUT CLINICAL TRIAL PHASES OF VARIOUS DRUGS TABLE 2 INCIDENCE AND PREVALENCE IN PAST DECADE (REGION) TABLE 3 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 4 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 5 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 6 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 7 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 9 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 10 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 11 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 12 NORTH AMERICA SURGICAL TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 13 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 15 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 16 NORTH AMERICA HOSPITAL IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 17 NORTH AMERICA SPECIALTY CLINICS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 18 NORTH AMERICA HOMECARE SETTINGS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 19 NORTH AMERICA OTHERS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 21 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 22 NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 23 NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 24 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 25 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 26 NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 27 NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 28 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 29 U.S. SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 30 U.S. LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 31 U.S. SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 32 U.S. SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 33 U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 34 U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 35 U.S. THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 36 U.S. SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 37 CANADA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 38 CANADA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 39 CANADA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 40 CANADA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 41 CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 42 CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 43 CANADA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 44 CANADA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 45 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 46 MEXICO LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 47 MEXICO SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 48 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 49 MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 50 MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 51 MEXICO THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 52 MEXICO SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)

 

LIST OF FIGURES NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET

FIGURE 1 BELOW IS THE SCLERODERMA MAP DEFINING THE TYPES FIGURE 2 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION FIGURE 3 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DATA TRIANGULATION FIGURE 4 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DROC ANALYSIS FIGURE 5 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS FIGURE 6 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS FIGURE 7 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS FIGURE 8 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET AND ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026 FIGURE 11 RISING CASES OF SCLERODERMA, INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S., INCREASING MERGER AND ACQUISITIONS IS EXPECTED TO DRIVE THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026 FIGURE 12 SYSTEMIC SCLERODERMA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN 2019 & 2026 FIGURE 13 NORTH AMERICA IS THE MAXIMUM GROWING AND MOST PROFI REVENUE POCKETS FOR NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026 FIGURE 14 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE , 2018 FIGURE 15 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TREATMENT TYPE , 2018 FIGURE 16 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY END USER, 2018 FIGURE 17 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018) FIGURE 18 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018) FIGURE 19 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026) FIGURE 20 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026) FIGURE 21 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026) FIGURE 22 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART